Blog
38 Articles
Exploring the Effectiveness of an Experimental Class of Drug
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
The Impact of BRCA Is Broader Than Breast and Ovarian Cancer
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.
Understanding a Family’s Risk for Pancreatic Cancer
A tumor registry studies the genetics of pancreatic cancer to determine risk factors for families.
When You Embrace the Enemy, It Changes Everything
Larry Clark describes how pancreatic cancer changed his retirement. He has pursued clinical trials as he faces recurring pancreatic cancer.
Understanding Family History Makes a Difference in Treatment Options
Elizabeth Pršić describes her mother Andrea’s pancreatic cancer treatment. Andrea has the BRCA2 mutation, which helps determine the plan.
Personalized Treatment Plans in the Fight Against PC
David Dessert explains that his aunt’s genetic testing for BRCA2 mutation directed his own treatment for pancreatic cancer.
My BRCA2 Mutation Turned Out to Be Both the Curse and the Cure
Sharon Seibel knew she had the BRCA2 mutation but was unaware of the link to pancreatic cancer. Her chemotherapy was one for BRCA carriers.